Technology Dev Core: The Center for Advancing Point of Care Technologies in Heart, Lung, Blood and Sleep Diseases

项目摘要/摘要-技术开发核心 心、肺、心、肺、肺等先进护理技术中心的目标 血液、睡眠疾病(HLBS)是开发和优化新的护理点技术 (POCT)以改进与HLBS相关疾病的诊断和管理。这些 疾病是美国发病率和死亡率的主要来源。POCT代表了 从在专业检测机构提供护理转变为 从床边，也从医疗中心到远程监控和家庭护理。CAPCaT 是基于非常成功的医疗产品孵化器，马萨诸塞州医疗设备 马萨诸塞大学洛厄尔和伍斯特大学发展中心(M2D2) 校园。UMassLowell在工程和商业方面有特别的优势，而 伍斯特校区是美国马萨诸塞州大学医学院的所在地，这是第一所也是唯一所公立 马萨诸塞州联邦学术健康科学中心。M2D2有一个 基础设施到位，为早期医疗设备提供一系列支持服务 公司致力于各种医学适应症，并在不同的临床节点 关心。CAPCaT将在M2D2上扩展，重点是HLBS疾病和POCT。这个 技术开发核心将从以下方面确定、选择和支持新的优秀项目 通过早期临床测试的原型。遴选将基于以下方面的表现和潜力 临床影响，并将提供支持，将利用UMassas现有资源的强大集合 Lowell和Wocester，以帮助开发现有的原型到临床 验证。

PROJECT SUMMARY/ABSTRACT – TECHNOLOGY DEVELOPMENT CORE The goal of the Center for Advancing Point of Care Technologies (CAPCaT) in Heart, Lung, Blood, and Sleep Diseases (HLBS) is to develop and optimize novel point of care technologies (POCT) to improve the diagnosis and management of disorders relating to HLBS. These disorders represent a major source of morbidity and mortality in the U.S. POCT represents an important tool in the transformation from delivering care in specialized testing facilities to the bedside, and also from medical centers to remote monitoring and home-based care. CAPCaT is based on the highly successful medical product incubator, the Massachusetts Medical Device Development Center (M2D2) at the University of Massachusetts (UMass) Lowell and Worcester campuses. UMass Lowell has particular strengths in engineering and business, while the Worcester campus houses the UMASS Medical School, which is the first and only public academic health sciences center in the Commonwealth of Massachusetts. M2D2 has an infrastructure in place that provides a range of support services to early-stage medical device companies working in a wide variety of medical indications, and at different nodes of clinical care. CAPCaT will expand on M2D2 with a specific focus HLBS disorders and on POCT. The Technology Development Core will identify, select, and support new meritorious projects from prototype through early clinical testing. Selection will be based on performance and potential for clinical impact, and will support will utilize a strong collection of existing resources at UMass Lowell and Worcester in order to help develop existing prototypes to the point of clinical validation.